Skip to main content
SpringerLink
Log in

Brentuximab vedotin containing salvage followed by consolidation post autologous hematopoietic stem cell transplantation in high risk relapsed refractory classical Hodgkin lymphoma

  • Correspondence
  • Published:
Bone Marrow Transplantation Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Progression free survival (PFS) and overall survival (OS) post autologous HCT.

References

  1. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet. 2002;359:2065–71.

    Article  CAS  Google Scholar 

  2. Majhail NS, Farnia SH, Carpenter PA, Champlin RE, Crawford S, Marks DI, et al. Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transpl. 2015;21:1863–9.

    Article  Google Scholar 

  3. Hahn T, McCarthy PL, Carreras J, Zhang MJ, Lazarus HM, Laport GG, et al. Simplified validated prognostic model for progression-free survival after autologous transplantation for Hodgkin lymphoma. Biol Blood Marrow Transpl. 2013;19:1740–4.

    Article  Google Scholar 

  4. Devillier R, Coso D, Castagna L, Brenot Rossi I, Anastasia A, Chiti A, et al. Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin’s lymphoma responding to prior salvage therapy. Haematologica. 2012;97:1073–9.

    Article  Google Scholar 

  5. Moskowitz CH, Matasar MJ, Zelenetz AD, Nimer SD, Gerecitano J, Hamlin P, et al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood. 2012;119:1665–70.

    Article  CAS  Google Scholar 

  6. Damlaj M, Ghazi S, Syed G, Pasha T, Gmati G, Salama H, et al. Pre-autologous transplantation PET/CT using Deauville criteria is an independent predictor of progression in relapsed refractory classical Hodgkin lymphoma. Bone Marrow Transpl. 2017;52:1342–4.

    Article  CAS  Google Scholar 

  7. Moskowitz CH, Walewski J, Nademanee A, Masszi T, Agura E, Holowiecki J, et al. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood. 2018;132:2639–42.

    Article  CAS  Google Scholar 

  8. LaCasce AS, Bociek RG, Sawas A, Caimi P, Agura E, Matous J, et al. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood. 2018;132:40–8.

    Article  CAS  Google Scholar 

  9. Garcia-Sanz R, Sureda A, de la Cruz F, Canales M, Gonzalez AP, Pinana JL, et al. Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group). Ann Oncol. 2019;30:612–20.

    Article  CAS  Google Scholar 

  10. Abuelgasim KA, Alzahrani M, Alsharhan Y, Khairi M, Hommady M, Gmati G, et al. Chemoimmunotherapy with brentuximab vedotin combined with ifosfamide, gemcitabine, and vinorelbine is highly active in relapsed or refractory classical Hodgkin lymphoma. Bone Marrow Transpl. 2019;54:1168–72.

    Article  Google Scholar 

  11. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059–68.

    Article  Google Scholar 

  12. Kanate AS, Kumar A, Dreger P, Dreyling M, Le Gouill S, Corradini P, et al. Maintenance therapies for hodgkin and non-hodgkin lymphomas after autologous transplantation: a consensus project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT. JAMA Oncol. 2019;5:715–22.

    Article  Google Scholar 

  13. Hagenbeek A, Mooij H, Zijlstra J, Lugtenburg P, van Imhoff G, Nijland M, et al. Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: the HOVON/LLPC Transplant BRaVE study. Haematologica. 2019;104:e151–3.

    Article  CAS  Google Scholar 

  14. Kort J, Chidiac A, El Sayed R, Massoud R, Nehme R, Bazarbachi A, et al. Safety and efficacy of four cycles of Brentuximab Vedotin as consolidation after autologous peripheral stem cell transplantation in relapsed/refractory Hodgkin lymphoma. Leuk Lymphoma. 2020:1–4.

Download references

Author information

Authors and Affiliations

  1. Division of Hematology & HSCT, Department of Oncology, King Abdulaziz Medical City, Riyadh, Saudi Arabia

    Moussab Damlaj, Khadega A. Abuelgasim, Ayman Alhejazi, Bader Alahmari, Ahmed Alaskar & Mohsen Alzahrani

  2. King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia

    Moussab Damlaj, Khadega A. Abuelgasim, Ayman Alhejazi, Bader Alahmari, Ahmed Alaskar & Mohsen Alzahrani

  3. King Abdullah International Medical Research Center, Riyadh, Saudi Arabia

    Moussab Damlaj, Khadega A. Abuelgasim, Ayman Alhejazi, Bader Alahmari, Ahmed Alaskar & Mohsen Alzahrani

Authors
  1. Moussab Damlaj
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Khadega A. Abuelgasim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ayman Alhejazi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bader Alahmari
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ahmed Alaskar
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mohsen Alzahrani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Moussab Damlaj.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Damlaj, M., Abuelgasim, K.A., Alhejazi, A. et al. Brentuximab vedotin containing salvage followed by consolidation post autologous hematopoietic stem cell transplantation in high risk relapsed refractory classical Hodgkin lymphoma. Bone Marrow Transplant 55, 2322–2325 (2020). https://doi.org/10.1038/s41409-020-0935-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-020-0935-0

  • Springer Nature Limited

This article is cited by

Search

Navigation